Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim add-on therapy in hospitalized adults with moderate II COVID-19
jRCT2031200180Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Sargramostim + standard treatment with Placebo + standard treatment (2 arms). Primary endpoint: Time to at least 2-rank improvement on 7-point ordinal scale. Started Feb 2021; status: completed.
02
Drugs
sargramostim
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031200180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200180.